Document:

Certain
identified information has been omitted because the omitted information is (i) not material and (ii) would likely cause competitive
harm to OncoCyte Corporation if publicly disclosed. Omitted portions of this exhibit are marked [**].

 

Final
Form

 

MINORITY
HOLDER STOCK PURCHASE AGREEMENT 

 

THIS
MINORITY HOLDER STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of September
[●], 2019, by and between (i) OncoCyte Corporation, a California corporation (“Buyer”),
and (ii) the individual named as the Minority Holder on the signature page hereto (the “Minority Holder”).
Any capitalized term used but not defined in this Agreement will have the meaning ascribed to such term in the SSPA (as defined
below).

 

WHEREAS,
the Minority Holder owns shares of common stock, par value $0.0001 per share (“Common Stock”), of Razor
Genomics Inc., a Delaware corporation (the “Company”), and/or owns options to purchase shares of Common
Stock (“Company Options”), as set forth on Exhibit A hereto;

 

WHEREAS,
on September 4, 2019, Buyer, the Company and Encore Clinical, Inc., a Delaware corporation (“Parent”),
entered into to that certain Subscription and Stock Purchase Agreement (the “SSPA”), a copy of which
has been provided to the Minority Holder, pursuant to which (i) the Company agreed to purchase and redeem from Parent, and Parent
agreed to sell and transfer to the Company, at the initial closing thereunder (the “Initial Closing”)
664,935 shares of the Common Stock (the “Redemption Shares”), constituting approximately 14.29% of the
issued and outstanding equity securities of the Company on a fully-diluted basis prior to giving effect to the Redemption or the
Subscription, at an aggregate redemption price of $5,000,000 (the “Redemption”), (ii) the Company agreed
to issue and sell to Buyer, and Buyer agreed to subscribe and purchase from the Company, at the Initial Closing 1,329,870 shares
(the “Subscribed Shares”) of newly created Series A Convertible Preferred Stock, par value $0.0001 per
share, of the Company (the “Preferred Stock”), which will constitute twenty-five percent (25%) of the
issued and outstanding equity interests on a fully-diluted basis of the Company after giving effect to the Redemption, at an aggregate
purchase price of $10,000,000 (the “Subscription”), and (iii) after the Initial Closing, at such times
and subject to such conditions as set forth in the SSPA, including the exercise of Buyer’s purchase option thereunder, Parent
agreed to sell and transfer to Buyer, and Buyer agreed to purchase and acquire from Parent, the remaining shares of Common Stock
owned by Parent (the consummation of such transaction, the “Second Closing”); and

 

WHEREAS,
subject to the terms and conditions of this Agreement, the Minority Holder desires (i) to acknowledge and consent to the transactions
contemplated by the SSPA and the Ancillary Documents and waive certain claims in connection therewith, (ii) if such Minority Holder
holds any Company Options, to exercise its Company Options upon the consummation of the transactions contemplated by this Agreement,
and (iii) to sell and transfer to Buyer, and Buyer desires to purchase and acquire from the Minority Holder, the equity interests
of the Company owned by the Minority Holder.

 

NOW,
THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth
below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereto agree as follows:

 

    	 

    	 

    

 

ARTICLE
I.

ACKNOWLEDGEMENT, CONSENT AND WAIVER

 

1.1
Acknowledgement. The Minority Holder hereby acknowledges that it has received a copy of the SSPA and has had the opportunity
to ask and receive answers from the Company and Buyer to any questions concerning this Agreement and the transactions contemplated
hereby and the SSPA and the Ancillary Documents and the transactions contemplated thereby. The Minority Holder hereby acknowledges
that Parent, which owns a majority of the issued and outstanding shares of the Company, and which is owned by two of the officers
and directors of the Company, will be treated differently from other shareholders of the Company under the SSPA and the Ancillary
Documents, including (i) having a portion of Parent’s shares redeemed in the Redemption at the Initial Closing at a price
per share higher than that to be paid at the Minority Holder Closing to the Minority Holder for the Minority Holder Shares (as
defined below) hereunder, (ii) Parent receiving compensation from Buyer, initially in the amount of $500,000 per year, pursuant
to a consulting agreement to be entered into by Buyer and Parent in connection with the Development Agreement and the License
Agreement, (iii) Parent receiving a milestone cash payment of $1,000,000 at the Initial Closing and having the ability to receive
additional milestone payments of $4,000,000 in cash after the Initial Closing pursuant to the Development Agreement, (iv) Parent
being entitled under the Development Agreement to receive a portion of any funding provided by a third party pharmaceutical company
to the Company or Buyer for the Clinical Trial, and (v) Parent continuing to receive certain payments for services provided in
support of the Company’s CLIA laboratory under the Laboratory Agreement between the Company and Parent, which payment obligations
for periods after the Initial Closing (other than certain existing obligations) will be made by Buyer, none of which rights under
clauses (i) through (v) above will be available to the Minority Holders.

 

1.2
Consent and Waiver. The Minority Holder hereby consents to the terms and conditions of, and the transactions contemplated
by, the SSPA and the Ancillary Documents for all purposes, and irrevocably waives and releases any potential rights, claims or
Actions (whether under this Agreement, the Company’s Governing Documents, applicable Law or otherwise) with respect thereto,
including (i) any rights (whether under the Company’s Governing Documents, applicable Law or otherwise) to equal pro rata
treatment based on its ownership of Company Common Stock (or Company Options exercisable for Company Common Stock), and (ii) any
rights, claims or Actions in connection with the disparate treatment among the Company’s shareholders and the additional
or different compensation or payments or rights that may be available to Parent or its equity holders or the officers or directors
of the Company in connection therewith.

 

ARTICLE
II.

PURCHASE AND SALE

 

2.1
Optionholder. If the Second Closing Purchase Option is exercised by Buyer in accordance with the terms of the SSPA, Buyer
will provide written notice thereof to the Minority Holder, and, if the Minority Holder owns any Company Options, the Minority
Holder agrees to, in accordance with the plan documents for the Company Option and/or its agreement with the Company with respect
to such Company Option, prior to the Minority Holder Closing: (a) for any Company Option that has vested and is in-the-money,
exercise the Company Option and sell to Buyer at the Minority Holder Closing pursuant to the terms of Section 2.2 the shares
of Common Stock to be issued to the Minority Holder upon the exercise thereof as part of the Minority Holder Shares; and (b) for
any Company Option that has not vested or is out-of-the-money, cancel and retire such Company Option at the Minority Holder Closing.

 

    	 

    	 

    

 

2.2
Minority Purchase. If the Second Closing Purchase Option is exercised by Buyer in accordance with the terms of the SSPA,
Buyer will provide written notice thereof to the Minority Holder, and subject to the terms and conditions set forth in this Agreement,
at the Minority Holder Closing the Minority Holder will sell, transfer, assign, convey and deliver to Buyer, free and clear of
any and all Liens, and Buyer will purchase and accept from the Minority Holder, all of the issued and outstanding equity interest
of the Company owned by the Minority Holder (including after giving effect to Section 2.1) (the “Minority Holder
Shares”), for an aggregate purchase price equal to (the “Purchase Price”) (a) Fifteen
Million U.S. Dollars ($15,000,000) multiplied by (b) a fraction, expressed as a percentage, equal to (i) the number of Minority
Holder Shares, divided by (ii) the total number of Purchased Shares under the SSPA (such fraction, the Minority Holder’s
“Pro Rata Share”). The Minority Holder hereby acknowledges and agrees that Buyer has no obligation under
this Agreement to exercise the Second Closing Purchase Option or to consummate the Second Closing under the SSPA.

 

2.3
Payment of Purchase Price. If the Second Closing Purchase Option is exercised by Buyer, at the Minority Holder Closing,
Buyer shall pay to the Minority Holder the Purchase Price as follows:

 

(a)
amount in cash equal to the product of (i) Ten Million U.S. Dollars ($10,000,000), multiplied by (ii) the Minority Holder’s
Pro Rata Share (the “Cash Payment”), by wire transfer in immediately available funds to the bank account
that is designated by the Minority Holder on Exhibit B (or such other bank account as the Minority Holder may designate
in writing after the date of this Agreement); and

 

(b)
a number of shares of Buyer Common Stock equal in value to the product of (i) Five Million U.S. Dollars ($5,000,000), multiplied
by (ii) the Minority Holder’s Pro Rata Share, with each such share of Buyer Common Stock valued at the Buyer Common Stock
Price as of the Second Closing Date (such shares of Buyer Common Stock, the “Minority Holder Buyer Shares”);

 

provided,
that (i) if Buyer would be required by Section 2.3(b) (and the applicable provisions of the SSPA and the other Minority
Holder Purchase Agreements, together with any shares of Buyer Common Stock issuable to Company Holders under or in connection
with the Development Agreement) to issue to the Company Holders more than 19.99% of the issued and outstanding shares of Buyer
Common Stock or the outstanding voting power of Buyer, in either case as of the date of the SSPA prior to giving effect to such
issuance, or if such issuance would otherwise require the approval of Buyer’s stockholders pursuant to the rules and regulations
of the NYSE American or other applicable law, regulation or rule, then Buyer, at its sole election, may deliver additional cash
in lieu of shares of Buyer Common Stock to the extent that such cash delivery avoids such Buyer Common Stock issuance exceeding
such 19.99% threshold or otherwise requiring Buyer shareholder approval; and (ii) no fractional shares of Buyer Common Stock will
be issued by Buyer and any fractional numbers will be rounded down to the nearest whole share and any fractional amount will instead
be added to the amount of cash paid pursuant to subsection (a).

 

2.4
Rights to Certain Payments under the Development Agreement and the License Agreement. The parties hereby acknowledge that
the Minority Holder will be entitled to receive a pro rata portion (based on (i) prior to the Second Closing, the shares of the
Company owned by the Minority Holder at such time as percentage of the Company’s outstanding equity on a fully-diluted basis
and (ii) at or after the Second Closing, the Minority Holder’s Pro Rata Share) of (a) the quarterly royalty payments based
on Net Cash Revenues (as defined in the License Agreement) under Section 4(e) of the License Agreement and (b) the milestone payment
of additional shares of Buyer Common Stock based on completion of enrollment in the Clinical Trial for the full number of patients
thereunder under Section 6.4 of the Development Agreement. Notwithstanding the foregoing, the Minority Holder hereby acknowledges
that it is not a party under the Development Agreement or the License Agreement and will not have rights as a party thereunder,
including any rights to dispute the amount of the Net Cash Revenues or the aggregate royalty payments under the License Agreement
or whether the milestone in Section 6.4 of the Development Agreement has been achieved or the amount of the applicable Buyer Common
Stock Price, that any such determinations will be made by the parties thereto, including Parent, and the Minority Holder will
receive the applicable payments based on the amounts as determined by Parent and if and at such time as when such payments are
made to Parent.

 

    	 

    	 

    

 

ARTICLE
III.

MINORITY HOLDER CLOSING; CLOSING CONDITIONS

 

3.1
Minority Holder Closing. If the Second Closing Purchase Option is exercised by Buyer, subject to the satisfaction or waiver
of the conditions set forth in Sections 3.2 and 3.2 below, the closing of the purchase and sale of the Minority
Holder Shares (the “Minority Holder Closing”) shall take place simultaneously with the consummation
of the Second Closing under the SSPA at the offices of Ellenoff, Grossman & Schole LLP, 1345 Avenue of the Americas, 11th
Floor, New York, NY 10105, or at such other place as the parties may mutually agree. The Minority Holder Closing may take place
by conference call, telecopy and email with exchange of original signatures by overnight mail. The Minority Holder Closing shall
be deemed effective for all purposes simultaneously with the Second Closing. The date on which the Minority Holder Closing occurs
will be referred to as the “Minority Holder Closing Date”

 

3.2
Buyer Conditions to Minority Holder Closing. The obligations of Buyer to consummate the Minority Holder Closing is subject
to the satisfaction or written waiver by Buyer where permissible of the following conditions:

 

(a)
the Second Closing (as defined in the SSPA) shall have occurred simultaneously with the Minority Holder Closing;

 

(b)
all of the representations and warranties of the Minority Holder set forth in this Agreement and in any certificate delivered
by or on behalf of the Minority Holder pursuant hereto will be true and correct in all material respects on and as of the Minority
Holder Closing Date as if made on the Minority Holder Closing Date (other than those that expressly address matters only as of
particular date, in which case as of such date);

 

(c)
the Minority Holder has performed and complied with, in all material respects, its covenants and agreements hereunder that are
required to be performed or complied with on or prior to the Minority Holder Closing Date; and

 

(d)
the Minority Holder shall have delivered or caused to be delivered to Buyer:

 

(i)
a certificates or certificates representing the Minority Holder Shares, duly endorsed or accompanied by powers duly executed and
in a form acceptable to Buyer necessary to transfer the Minority Holder Shares to Buyer on the books and records of the Company;

 

(ii)
a completed and duly executed IRS Form W-9 or W-8BEN, as applicable;

 

(iii)
a certificate, dated as of the Minority Holder Closing Date, signed by the Minority Holder, certifying that each of the conditions
specified in Sections 3.2(b) and 3.2(c) has been satisfied; and

 

(iv)
such other documents and instruments as may be required to be delivered by the Minority Holder to Buyer at or prior to the Minority
Holder Closing by any other provision of this Agreement or as may reasonably be required to transfer the Minority Holder Shares
to Buyer or to consummate the Minority Holder Closing (or the Second Closing) or any of the transactions contemplated by the Ancillary
Documents to be executed and delivered in connection with the Minority Holder Closing.

 

    	 

    	 

    

 

3.3
Minority Holder Conditions to Minority Holder Closing. The obligations of the Minority Holder to consummate the Minority
Holder Closing is subject to the satisfaction or written waiver by the Minority Holder where permissible of the following conditions:

 

(a)
the Second Closing (as defined in the SSPA) shall have occurred simultaneously with the Minority Holder Closing;

 

(b)
all of the representations and warranties of Buyer set forth in this Agreement and in any certificate delivered by or on behalf
of Buyer pursuant hereto will be true and correct in all material respects on and as of the Minority Holder Closing Date as if
made on the Minority Holder Closing Date (other than those that expressly address matters only as of particular date, in which
case as of such date);

 

(c)
Buyer has performed and complied with, in all material respects, its covenants and agreements hereunder that are required to be
performed or complied with on or prior to the Minority Holder Closing Date; and

 

(d)
Buyer shall have delivered or caused to be delivered to the Minority Holder:

 

(i)
the Cash Payment;

 

(ii)
evidence that the Minority Holder Buyer Shares have been issued to the Minority Holder;

 

(iii)
a certificate, dated as of the Minority Holder Closing Date, signed by an executive officer of Buyer, certifying that each of
the conditions specified in Sections 3.3(b) and 3.3(c) has been satisfied; and

 

(iv)
such other documents and instruments as may be required to be delivered by Buyer to the Minority Holder at or prior to the Minority
Holder Closing by any other provision of this Agreement.

 

ARTICLE
IV.

TERMINATION; CANCELLATION

 

4.1
Termination.

 

(a)
In the event that the SSPA is validly terminated in accordance with the terms thereof prior to the Initial Closing for any reason,
this Agreement shall automatically terminate and be of no further force or effect.

 

(b)
In addition, this Agreement may be terminated, and the transactions contemplated may be abandoned, at any time prior to the Initial
Closing by Buyer by providing written notice thereof to the Minority Holder if (i) there has been a breach by the Minority Holder
of any of its representations, warranties, covenants or agreements contained in this Agreement, or if any representation or warranty
of the Minority Holder shall have become untrue or inaccurate, in any case, which would result in a failure of a condition set
forth in Section 3.2(b) or 3.2(c) to be satisfied (treating the Initial Closing Date for such purposes as the date
of this Agreement or, if later, the date of such breach), and (ii) the breach or inaccuracy is incapable of being cured or is
not cured within the earlier of (A) [**] after written notice of such breach or inaccuracy is provided to the Minority Holder
by Buyer or (B) the Outside Date; provided, that Buyer shall not have the right to terminate this Agreement pursuant to this Section
4.1(b) if at such time Buyer is in material uncured breach of this Agreement.

 

    	 

    	 

    

 

(c)
In the event of any termination of this Agreement pursuant to this Section 4.1, the obligations of the parties hereunder
with respect to the Minority Holder Closing shall forthwith become null and void, and there shall be no liability on the part
of any party or any of their respective Representatives, and all rights and obligations of each party with respect to the Minority
Holder Closing shall cease. Notwithstanding anything to the contrary, no termination of this Agreement shall affect (i) the provisions
of, or any obligations of the parties under, Section 7.3 or ARTICLE I or ARTICLE VIII hereof, or this Section
4.1, which Sections and Articles shall survive any termination of this Agreement or (ii) any Liability of a party for a willful
breach or violation of this Agreement or any Fraud Claim against such party, in either case, prior to such termination.

 

4.2
Cancellation of Minority Holder Closing.

 

(a)
Notwithstanding anything to the contrary herein, if the exercise of the Second Closing Purchase Option is cancelled by Buyer in
accordance with Section 4.5 of the SSPA prior to the Minority Holder Closing, then the exercise of the Second Closing Purchase
Option with respect to the Minority Holder shall also automatically be cancelled.

 

(b)
Additionally, the exercise of the Second Closing Purchase Option with respect to the Minority Holder may be cancelled at any time
prior to the Minority Holder Closing by Buyer by providing written notice thereof to the Minority Holder if (i) there has been
a breach by the Minority Holder of any of its representations, warranties, covenants or agreements contained in this Agreement,
or if any representation or warranty of the Minority Holder shall have become untrue or inaccurate, in any case, which would result
in a failure of a condition set forth in Section 3.2(b) or 3.2(c) to be satisfied (treating the Minority Holder
Closing Date for such purposes as the date of this Agreement or, if later, the date of such breach), and (ii) the breach or inaccuracy
is incapable of being cured or is not cured within the earlier of (A) [**] after written notice of such breach or inaccuracy is
provided to the Minority Holder by Buyer or (B) the Second Closing Outside Date; provided, that Buyer shall not have the right
to cancel the exercise of the Second Closing Purchase Option pursuant to this Section 4.2(b) if at such time Buyer is in
material uncured breach of this Agreement.

 

(c)
In the event that the exercise of the Second Closing Purchase Option is cancelled in accordance with this Section 4.2,
the obligations of the parties to consummate the Minority Holder Closing as a result of the exercise of such Second Closing Purchase
Option shall become null and void; provided, that such cancellation will not relieve a party for a willful breach or violation
of this Agreement or for any Fraud Claim against such party, in either case, prior to such cancellation. If the exercise of the
Second Closing Purchase Option is cancelled in accordance with this Section 4.2, Buyer will retain the right under the
SSPA and this Agreement to exercise the Second Closing Purchase Option, at its sole election, at any time following [**], but
not later than [**], after such cancellation.

 

    	 

    	 

    

 

ARTICLE
V.

REPRESENTATIONS AND WARRANTIES OF THE MINORITY HOLDER

 

The
Minority Holder represents and warrants to Buyer as of the date hereof and as of the Minority Holder Closing as follows:

 

5.1
Organization; Authority; Binding Agreement. If the Minority Holder is an entity, the Minority Holder has been duly formed
or organized, is validly existing and in good standing under the Laws of its jurisdiction of organization and has all requisite
corporate or other organizational power and authority to own, lease and operate its properties and to carry on its business as
now being conducted. The Minority Holder has the full power and authority to enter into this Agreement and the Ancillary Documents
to which it is or is required to be a party and to consummate the transactions contemplated hereby and thereby and to perform
its obligations hereunder and thereunder. This Agreement has been, and each Ancillary Document to which the Minority Holder is
or is required to be a party shall be when delivered, duly executed and delivered by the Minority Holder and, assuming the due
authorization, execution and delivery of this Agreement and any such Ancillary Documents by the other parties hereto and thereto,
constitutes, or when delivered shall constitute, the legal, valid and binding obligation of the Minority Holder, enforceable against
the Minority Holder in accordance with its terms, except as the enforceability thereof may be limited by the Enforceability Exceptions.

 

5.2
Title to Shares. The Minority Holder owns good, valid and marketable title to its portion of the Purchased Shares as set
forth next to its name on Exhibit A hereto, free and clear of any and all Liens (other than those imposed by applicable
securities Laws, the Company’s Governing Documents and the rights of Buyer under this Agreement). Upon delivery of the Minority
Holder Shares to Buyer at the Minority Holder Closing in accordance with this Agreement, the entire legal and beneficial interest
in the Minority Holder Shares and good, valid and marketable title to the Minority Holder Shares, free and clear of all Liens
(other than those imposed by applicable securities Laws, the Company’s Governing Documents or those incurred by Buyer),
will pass to the Buyer.

 

5.3
Governmental Approvals. No Consent of or with any Governmental Authority on the part of the Minority Holder is required
to be obtained or made in connection with the execution, delivery or performance by the Minority Holder of this Agreement or any
Ancillary Document to which the Minority Holder is a party or otherwise bound or the consummation by the Minority Holder of the
transactions contemplated hereby or thereby.

 

5.4
No Violations. Neither the execution, delivery and performance of this Agreement or any Ancillary Documents by the Minority
Holder, nor the consummation of the transactions contemplated hereby or thereby, will (a) if, the Minority Holder is an entity,
violate or conflict with, any provision of its Governing Documents, (b) violate or conflict with any Law or Order to which the
Minority Holder or its assets or the Minority Holder Shares are bound or subject, (c) with or without giving notice or the lapse
of time or both, breach or conflict with, constitute or create a default under, or give rise to any right of termination, cancellation
or acceleration of any obligation or result in a loss of a material benefit under, or give rise to any obligation of the Minority
Holder to make any payment under, or to the increased, additional, accelerated or guaranteed rights or entitlements of any Person
under, any of the terms, conditions or provisions of any Contract, agreement, or other commitment to which the Minority Holder
is a party or by which the Minority Holder, its assets or the Minority Holder Shares may be bound, (d) result in the imposition
of a Lien (other than a Permitted Lien) on any of the Minority Holder Shares or (e) require any Consent of or with, any Person
(other than any Governmental Authority).

 

5.5
Investment Intent. At the Minority Holder Closing, the Minority Holder is acquiring the Minority Holder Buyer Shares for
its own account and not with a view to its distribution within the meaning of Section 2(11) of the Securities Act, and the rules
and regulations issued pursuant thereto. The Minority Holder is an “accredited investor” within the meaning of Rule
501 under the Securities Act. The Minority Holder understands that, the Minority Holder Buyer Shares will not be registered under
the Securities Act and cannot be sold unless subsequently registered under the Securities Act or an exemption from such registration
is available.

 

    	 

    	 

    

 

5.6
No Brokers. Neither the Minority Holder, nor any of its Representatives on its behalf, has employed any broker, finder
or investment banker or incurred any liability for any brokerage fees, commissions, finders’ fees or similar fees in connection
with the transactions contemplated by this Agreement.

 

5.7
No Inducements. The Minority Holder hereby acknowledges that none of the Company, Buyer or Parent nor any other Person
has made, and the Minority Holder is not relying upon, any oral or written representation, inducement, promise or agreement to
the Minority Holder in connection with the consummation of the transactions contemplated by this Agreement, other than as expressly
set forth in this Agreement.

 

ARTICLE
VI.

REPRESENTATIONS AND WARRANTIES OF BUYER

 

Buyer
represents and warrants to the Minority Holder as of the date hereof and as of the Minority Closing as follows:

 

6.1
Organization and Qualification. Buyer has been duly formed or organized, is validly existing and in good standing under
the Laws of the State of California and has all requisite corporate or other organizational power and authority to own, lease
and operate its properties and to carry on its business as now being conducted.

 

6.2
Authorization; Binding Agreement. Buyer has full power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby and to perform its obligations hereunder. Buyer has duly authorized by all necessary action on
the part of Buyer the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby. This
Agreement has been duly executed and delivered by Buyer and, assuming the due authorization, execution and delivery of this Agreement
by the other parties hereto, constitutes the legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance
with its terms, except as the enforceability thereof may be limited by the Enforceability Exceptions.

 

6.3
No Violations. Neither the execution and delivery of this Agreement by Buyer, nor the consummation of the transactions
contemplated hereby, will violate or conflict with or (with or without notice or the passage of time or both) constitute a breach
or default under (a) any provision of Buyer’s Governing Documents, (b) any Law or Order to which Buyer or its business or
assets are bound or subject or (c) any Contract or Permit to which Buyer is a party or by which Buyer or any of its properties
may be bound or affected, other than, in the cases of clauses (a) through (c), such violations and conflicts which would not,
individually or in the aggregate, reasonably be expected to have a Buyer Material Adverse Effect.

 

6.4
Title to Minority Holder Buyer Shares. The Minority Holder Buyer Shares, when issued and delivered and paid for in compliance
with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will not have been issued in
violation of or subject to any preemptive or similar rights created under Buyer’s Governing Documents or under the laws
of the State of California. Upon the issuance of the Minority Holder Buyer Shares to the Minority Holder at the Minority Holder
Closing, the Minority Holder will own good, valid and marketable title to the Minority Holder Buyer Shares, free and clear of
any and all Liens (other than those imposed by applicable securities Laws, Buyer’s Governing Documents or those incurred
by the Minority Holder). Assuming the accuracy of the representations and warranties of the Minority Holder in Section 5.5,
the representations and warranties of Parent in Section 6.22 of the SSPA, and similar representations and warranties made
by the other Minority Holders in the other Minority Holder Purchase Agreements, the offer, sale and issuance of the Minority Holder
Buyer Shares are exempt from the registration requirements of the Securities Act and have been registered or qualified (or exempt
from registration and qualification) under the registration, permit or qualification requirements of all applicable state securities
or “blue sky” Laws.

 

    	 

    	 

    

 

6.5
Governmental Approvals. No Consent of or with any Governmental Authority is required on the part of Buyer in connection
with the consummation of the transactions contemplated by this Agreement, other than (i) such filings as may be required in any
jurisdiction where Buyer is qualified or authorized to do business as a foreign corporation in order to maintain such qualification
or authorization, (ii) such filings as contemplated by this Agreement or the SSPA, (iii) applicable requirements, if any, of the
Securities Act, the Exchange Act or any state “blue sky” securities Laws, and the rules and regulations thereunder,
and (iv) where the failure to obtain or make such Consents would not reasonably be expected to have a Buyer Material Adverse Effect.

 

6.6
Investment Intent. Buyer is acquiring the Minority Holder Shares at the Minority Holder Closing for its own account and
not with a view to their distribution within the meaning of Section 2(11) of the Securities Act. Buyer understands that the Minority
Holder Shares have not been registered under the Securities Act, and cannot be sold unless subsequently registered under the Securities
Act or an exemption from such registration is available. Buyer is an “accredited investor”, as defined in Rule 501(a)
promulgated under the Securities Act.

 

6.7
No Brokers. Neither Buyer, nor any Representative of Buyer on its behalf, has employed any broker, finder or investment
banker or incurred any liability for any brokerage fees, commissions, finders’ fees or similar fees in connection with the
transactions contemplated by this Agreement.

 

6.8
No Other Representations and Warranties. Except for the representations and warranties contained in or this ARTICLE
VI, Buyer makes no express or implied representations or warranties, and hereby disclaims any other representations and warranties,
whether made orally or in writing, by or on behalf of Buyer by any Person.

 

ARTICLE
VII.

ADDITIONAL AGREEMENTS

 

7.1
Prohibition on Transfer. The Minority Holder hereby covenants and agrees that during the period from the date of this Agreement
and continuing until the earlier of the (x) the Minority Holder Closing or (y) the termination of this Agreement in accordance
with Section 4.1 (the “Minority Holder Interim Period”), unless Buyer shall otherwise consent
in writing in its sole discretion, except as expressly contemplated by this Agreement, the Minority Holder shall not directly
or indirectly sell, assign, convey, dispose of or otherwise transfer any equity interests of the Company that it owns or any interests
therein (including through any hedging or derivative securities or contracts), or otherwise subject such equity interests to any
Lien (other than those imposed by applicable securities Laws or the Company’s Governing Documents). Any purported sale,
assignment, transfer, pledge, hypothecation or other Lien in violation of this Section 7.1 shall be null and void ab initio
and of no force or effect.

 

    	 

    	 

    

 

7.2
Efforts; Further Assurances. Subject to the terms and conditions of this Agreement, and subject to the sole discretion
of Buyer to exercise the Second Closing Purchase Option, each party shall use its commercially reasonable efforts, and shall cooperate
fully with the other party, to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper
or advisable under applicable Laws and regulations to consummate the transactions contemplated by this Agreement, and to comply
as promptly as practicable with all requirements of Governmental Authorities applicable to the transactions contemplated by this
Agreement. Subject to the exercise of the Second Closing Purchase Option, each party shall cooperate with the other party and
use its commercially reasonable efforts to take or cause to be taken all actions, and do or cause to be done all things, necessary,
proper or advisable on its part under this Agreement and applicable Laws to consummate the transactions contemplated by this Agreement
as soon as practicable, including preparing and filing as soon as practicable all documentation to effect all necessary notices,
reports and other filings and to obtain (in accordance with this Agreement) as soon as practicable all consents, registrations,
approvals, permits and authorizations necessary or advisable to be obtained from any third Person and/ or any Governmental Authority.

 

7.3
Public Announcements; No Insider Trading.

 

(a)
The Minority Holder will, and will cause its Representatives to, keep the terms and conditions of this Agreement, the SSPA and
the Ancillary Documents in strict confidence, and will not disclose this Agreement, the SSPA or the Ancillary Documents, the terms
and conditions hereof or thereof or the transactions contemplated hereby or thereby, or make or issue any public release or announcement
concerning the foregoing, without the prior written consent of Buyer, except (i) as such disclosure, release or announcement may
be required by applicable Law or the rules or regulations of the SEC or any applicable securities exchange, in which case the
Minority Holder shall use commercially reasonable efforts to allow Buyer reasonable time to comment on any such disclosure, and
arrange for any required filing with respect to, such disclosure, release or announcement in advance of such issuance, and (ii)
the Minority Holder may disclose the foregoing to its Representatives that reasonably need to know such information in connection
with assisting the Minority Holder with enforcing its rights and carrying out its obligations under this Agreement and the Ancillary
Documents, are advised of the confidential nature of such information and are subject to an obligation of confidentiality with
respect to such information.

 

(b)
The Minority Holder acknowledges and agrees that it is aware, and that its Affiliates are aware (and each of its Representatives
is aware or, upon receipt of any material nonpublic information of Buyer, will be advised) of the restrictions imposed by U.S.
federal securities Laws and other applicable foreign and domestic Laws on a Person possessing material nonpublic information about
a publicly traded company. The Minority Holder hereby agrees that, while it is in possession of such material nonpublic information
regarding Buyer, it shall not purchase or sell any securities of Buyer (other than its acquisition of the Minority Holder Buyer
Shares in accordance with the terms of this Agreement), communicate such information to any third party, take any other action
with respect to Buyer in violation of such Laws, or cause or encourage any third party to do any of the foregoing.

 

7.4
Release. Effective as of the Minority Holder Closing, the Minority Holder hereby releases and discharges the Company from
and against any and all Actions, obligations, agreements, debts and Liabilities whatsoever, whether known or unknown, both at
law and in equity, which the Minority Holder then has, has ever had or may thereafter have against the Company arising on or prior
to the Minority Holder Closing Date or on account of or arising out of any matter occurring on or prior to the Minority Holder
Closing Date, including any rights to indemnification or reimbursement from the Company, whether pursuant to its Governing Documents,
Contract or otherwise, and whether or not relating to claims pending on, or asserted after, the Minority Holder Closing Date.
From and after the Minority Holder Closing Date, the Minority Holder hereby irrevocably covenants to refrain from, directly or
indirectly, asserting any Action, or commencing or causing to be commenced, any Action of any kind against the Company or its
Affiliates, based upon any matter purported to be released hereby. Notwithstanding anything herein to the contrary, the releases
and restrictions set forth herein shall not apply to any claims the Minority Holder may have against any party pursuant to the
terms and conditions of this Agreement. The Minority Holder hereby acknowledges and agrees that the Company is an intended third
party beneficiary of this Section 7.4 and may enforce the terms hereof as it if were a direct party hereto.

 

    	 

    	 

    

 

7.5
Market Standoff Agreement. During the Minority Holder Interim Period, the Minority Holder shall not, directly or indirectly,
sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of Buyer without
the prior written consent of Buyer (not to be unreasonably withheld, delayed or conditioned).

 

7.6
Company Board of Directors. The Minority Holder shall take all necessary action, including voting its equity interests
of the Company accordingly, so that at all times from the Initial Closing through the Minority Holder Closing, the Company’s
board of directors shall consist of three (3) directors, and effective as of: (a) the Initial Closing, at least one director shall
be an individual designated by Buyer at or prior to the Initial Closing; and (b) the Minority Holder Closing, all of the directors
shall be individuals designated by Buyer at or prior to the Minority Holder Closing.

 

ARTICLE
VIII.

MISCELLANEOUS

 

8.1
Survival. The representations and warranties of the parties contained in this Agreement or in any certificate or instrument
delivered by or on behalf of the parties pursuant to this Agreement shall survive for a period of twelve (12) months after the
Minority Holder Closing. All covenants, obligations and agreements of the parties contained in this Agreement (including all certificates,
documents, instruments and undertakings furnished pursuant to this Agreement), shall survive the Minority Holder Closing and continue
until fully performed in accordance with their terms.

 

8.2
Fees and Expenses; Counsel. Each party will bear its own legal and other fees and expenses incurred in connection with
its negotiating, executing and performing this Agreement, including any related broker’s or finder’s fees.

 

8.3
Notices. Any notice, request, instruction or other document to be given hereunder by a party hereto shall be in writing
and shall be deemed to have been given, (i) when received if given in person or by courier or a courier service, (ii) on the date
of transmission if sent by facsimile or email (with affirmative confirmation of receipt, and provided, that the party providing
notice shall within two (2) Business Days provide notice by another method under this Section 8.3) or (iii) three (3) Business
Days after being deposited in the U.S. mail, certified or registered mail, postage prepaid:

 

	If
    to Buyer, to:	with a copy (which will not constitute notice) to:
	 	 
	OncoCyte
    Corporation	Ellenoff Grossman & Schole LLP
	1010
    Atlantic Avenue, Suite 102	1345 Avenue of the Americas,
	Alameda,
    California 94501	New York, NY 10105
	Attn:
    Albert P. Parker, COO	Attn:	Matthew
    A. Gray, Esq.;
	Telephone
    No: [**]	 	Robert
    Charron, Esq.
	Email:
    [**]	Facsimile: [**]
	 	Email: [**]
	 	 
	If to the Minority Holder, to the address of the Minority Holder set forth on Exhibit B hereto.

 

or
to such other individual or address as a party hereto may designate for itself by notice given as herein provided.

 

    	 

    	 

    

 

8.4
Severability. In case any one or more of the provisions contained in this Agreement should be held invalid, illegal or
unenforceable in any respect, the validity, legality, and enforceability of the remaining provisions will not in any way be affected
or impaired. Any illegal or unenforceable term will be deemed to be void and of no force and effect only to the minimum extent
necessary to bring such term within the provisions of applicable Law and such term, as so modified, and the balance of this Agreement
will then be fully enforceable. The parties will substitute for any invalid, illegal or unenforceable provision a suitable and
equitable provision that carries out, so far as may be valid, legal and enforceable, the intent and purpose of such invalid, illegal
or unenforceable provision.

 

8.5
Assignment. This Agreement may not be assigned by any party without the prior written consent of the other party, and any
attempted assignment in violation of this Section 8.4 will be null and void ab initio; provided, however,
that upon or after the Minority Holder Closing, Buyer may assign its rights and obligations hereunder: (i) to any Affiliate of
Buyer (provided, that Buyer shall remain primarily responsible for its obligations hereunder); (ii) to any Person acquiring all
or substantially all of the assets of Buyer and its Subsidiaries taken as a whole or a majority of the outstanding equity securities
of Buyer (whether by stock purchase, merger, consolidation or otherwise); provided, that the assignee expressly assumes
the obligations of Buyer hereunder; or (iii) as security to any Person providing debt financing to Buyer or its Affiliates for
any of the transactions contemplated by this Agreement. Subject to the preceding sentence, this Agreement will apply to, be binding
in all respects upon and inure to the benefit of the successors and permitted assigns of each party.

 

8.6
No Third Party Beneficiaries. Except with respect to the rights of the Company under Section 7.4, this Agreement
is for the sole benefit of the parties and their successors and permitted assigns and nothing herein expressed or implied shall
give or be construed to give to any Person, other than the parties and such successors and permitted assigns, any legal or equitable
rights hereunder.

 

8.7
Amendments: Waivers. This Agreement may not be amended or modified except by an instrument in writing signed by each party.
Notwithstanding anything to the contrary contained herein: (a) the failure of any party at any time to require performance by
any other party of any provision of this Agreement will not affect such party’s right thereafter to enforce the same; (b)
no waiver by any party of any default by any other party will be valid unless in writing and acknowledged by an authorized representative
of the non-defaulting party, and no such waiver will be taken or held to be a waiver by such party of any other preceding or subsequent
default; and (c) no extension of time granted by any party for the performance of any obligation or act by any other party will
be deemed to be an extension of time for the performance of any other obligation or act hereunder.

 

8.8
Entire Agreement; Conflicts with SSPA. This Agreement (including the exhibits hereto, which are incorporated herein by
reference and deemed part of this Agreement) and, to the extent incorporated herein, the SSPA, constitute the entire agreement
between the parties with respect to the subject matter hereof and referenced herein, and supersede and terminate any prior agreements
between the parties (written or oral) with respect to the subject matter hereof. Any description of the SSPA or the terms thereof
included in this Agreement (i) is provided for convenience of reference only, (ii) is subject to and qualified by the detailed
provisions in the SSPA, and (iii) shall not alter, amend or modify in any manner any term or provision of the SSPA.

 

    	 

    	 

    

 

8.9
Remedies. Except as specifically set forth in this Agreement, any party having any rights under any provision of this Agreement
will have all rights and remedies set forth in this Agreement and all rights and remedies which such party may have been granted
at any time under any other contract or agreement and all of the rights which such party may have under any applicable Law. Except
as specifically set forth in this Agreement, any such party will be entitled to (a) seek to enforce such rights specifically,
without posting a bond or other security or proving damages or that monetary damages would be inadequate, (b) to recover damages
by reason of a breach of any provision of this Agreement and (c) to exercise all other rights granted by applicable Law. The exercise
of any remedy by a party will not preclude the exercise of any other remedy by such party.

 

8.10
Arbitration. Any and all disputes, controversies and claims arising out of, related to, or in connection with this Agreement
or the transactions contemplated hereby (a “Dispute”) shall be governed by this Section 8.10.
A party must, in the first instance, provide written notice of any Disputes to the other parties subject to such Dispute, which
notice must provide a reasonably detailed description of the matters subject to the Dispute. The parties involved in such Dispute
shall seek to resolve the Dispute on an amicable basis within twenty (20) days of the notice of such Dispute being received by
such other parties subject to such Dispute; the “Resolution Period”); provided, that if any Dispute
would reasonably be expected to have become moot or otherwise irrelevant if not decided within sixty (60) days after the occurrence
of such Dispute, then there shall be no Resolution Period with respect to such Dispute. Any Dispute that is not resolved during
the Resolution Period may immediately be referred to and finally resolved by arbitration pursuant to the then-existing Expedited
Procedures (as defined in the AAA Procedures) of the Commercial Arbitration Rules (the “AAA Procedures”)
of the American Arbitration Association (the “AAA”). Any party involved in such Dispute may submit the
Dispute to the AAA to commence the proceedings after the Resolution Period. To the extent that the AAA Procedures and this Agreement
are in conflict, the terms of this Agreement shall control. The arbitration shall be conducted by one arbitrator nominated by
the AAA promptly (but in any event within five (5) Business Days) after the submission of the Dispute to the AAA and reasonably
acceptable to each party subject to the Dispute, which arbitrator shall be a commercial lawyer with substantial experience arbitrating
disputes under acquisition agreements. The arbitrator shall accept his or her appointment and begin the arbitration process promptly
(but in any event within five (5) Business Days) after his or her nomination and acceptance by the parties subject to the Dispute.
The proceedings shall be streamlined and efficient. The arbitrator shall decide the Dispute in accordance with the substantive
law of the State of Delaware. Time is of the essence. Each party subject to the Dispute shall submit a proposal for resolution
of the Dispute to the arbitrator within twenty (20) days after confirmation of the appointment of the arbitrator. The arbitrator
shall have the power to order any party to do, or to refrain from doing, anything consistent with this Agreement and applicable
Law, including to perform its contractual obligation(s); provided, that the arbitrator shall be limited to ordering pursuant to
the foregoing power (and, for the avoidance of doubt, shall order) the relevant party (or parties, as applicable) to comply with
only one or the other of the proposals. The arbitrator’s award shall be in writing and shall include a reasonable explanation
of the arbitrator’s reason(s) for selecting one or the other proposal. The seat of arbitration shall be in the State of
California, and the language of the arbitration shall be English.

 

8.11
Governing Law; Jurisdiction; Waiver
of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware
(without giving effect to its choice of law principles). Each of the parties (a) irrevocably submits to the exclusive jurisdiction
and venue of any state or federal court located in the State of California (and any appellate courts thereof), (b) agrees that
service of any process, summons, notice or document by U.S. registered mail to such party’s respective address set forth
in Section 8.3 shall be effective service of process for any Action with respect to any matters to which it has submitted
to jurisdiction in this Section 8.11, and (c) waives and covenants not to assert or plead, by way of motion, as a defense
or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of such court, that the Action
is brought in an inconvenient forum, that the venue of the Action is improper or that this Agreement, as applicable, or the subject
matter hereof or thereof may not be enforced in or by such court, and hereby agrees not to challenge such jurisdiction or venue
by reason of any offsets or counterclaims in any such Action. The parties hereby knowingly,
voluntarily and intentionally waive the right any may have to a trial by jury in respect to any litigation based hereon, or arising
out of, under, or in connection with this Agreement and any agreement contemplated to be executed in connection herewith, or any
course of conduct, course of dealing, statements (whether verbal or written) or actions of any party in connection with such agreements.

 

    	 

    	 

    

 

8.12
Interpretation. The headings and subheadings of this Agreement are for reference and convenience purposes only and in no
way modify, interpret or construe the meaning of specific provisions of the Agreement. In this Agreement, unless the context otherwise
requires: (i) whenever required by the context, any pronoun used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular form of nouns, pronouns and verbs shall include the plural and vice versa; (ii) reference
to any Person includes such Person’s successors and assigns but, if applicable, only if such successors and assigns are
permitted by this Agreement, and reference to a Person in a particular capacity excludes such Person in any other capacity; (iii)
any accounting term used and not otherwise defined in this Agreement has the meaning assigned to such term in accordance with
GAAP; (iv) “including” (and with correlative meaning “include”) shall be deemed in each case to be followed
by the words “without limitation”; (v) the words “herein,” “hereto,” and “hereby”
and other words of similar import in this Agreement shall be deemed in each case to refer to this Agreement as a whole and not
to any particular Section or other subdivision of this Agreement; (vi) the word “if” and other words of similar import
when used herein shall be deemed in each case to be followed by the phrase “and only if”; (vii) the term “or”
means “and/or”; (viii) reference to “dollars” or “$” shall mean U.S. Dollars; (ix) reference
to any statute includes any rules and regulations promulgated thereunder; (x) any agreement, instrument, insurance policy, Law
or Order defined or referred to herein or in any agreement or instrument that is referred to herein means such agreement, instrument,
insurance policy, Law or Order as from time to time amended, modified or supplemented, including (in the case of agreements or
instruments) by waiver or consent and (in the case of statutes, regulations, rules or orders) by succession of comparable successor
statutes, regulations, rules or orders and references to all attachments thereto and instruments incorporated therein; and (xi)
all references in this Agreement to the words “Section” and “Exhibit” are intended to refer to Sections
and Exhibits to this Agreement.

 

8.13
Mutual Drafting. The parties acknowledge and agree that: (a) this Agreement is the result of negotiations between the parties
and will not be deemed or construed as having been drafted by any one party, (b) each party and its counsel have reviewed and
negotiated the terms and provisions of this Agreement (including any, exhibits attached hereto) and have contributed to their
revision, (c) the rule of construction to the effect that any ambiguities are resolved against the drafting party will not be
employed in the interpretation of this Agreement and (d) neither the drafting history nor the negotiating history of this Agreement
may be used or referred to in connection with the construction or interpretation thereof.

 

8.14
Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties in separate counterparts,
each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same
agreement. A photocopy, faxed, scanned and/or emailed copy of this Agreement or any Ancillary Document or any signature page to
this Agreement or any Ancillary Document, shall have the same validity and enforceability as an originally signed copy.

 

{REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS}

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Minority Holder Purchase Agreement to be executed and delivered as of the
date first written above.

 

	 	Buyer:
	 	 	 
	 	ONCOCYTE
    CORPORATION
	 	 	 
	 	By:	 
	 	Name:	Ron
    A. Andrews
	 	Title:
    	President
    and Chief Executive Officer

 

[Signature
Page to Minority Holder Purchase Agreement]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Minority Holder Purchase Agreement to be executed and delivered as of the
date first written above.

 

	 	The
    Minority Holder:
	 	 
	 	 	 
	 	Print
    Name:

 

[Signature
Page to Minority Holder Purchase Agreement]

 

    	 

    	 

    

 

Exhibit
A

Company Equity Ownership

 

	Company
    Holder	 	Shares
of

                                                                                                                                                   Common Stock
	 	Company

                                                                                                                                                   Options
	 	Fully

                                                                                Diluted

                                                                                Shares
	 	Fully-Diluted Ownership

                                                                                Percentage*

	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	TOTAL	 	4,554,545	 	100,000	 	4,654,545	 	100.0%

 

*
Prior to giving effect to the Redemption or the Subscription

 

    	 

    	 

    

 

Exhibit
B

Minority
Holder Information

 

Name
of Minority Stockholder:______________________________________________________________________

 

Address
of Minority Stockholder for Notice: ___________________________________________________________

 

 ______________________________________________________________________________________________

 

______________________________________________________________________________________________

 

______________________________________________________________________________________________

 

Email:
_________________________________________________________________________________________

 

Telephone:_____________________________________________________________________________________

 

Wire
Transfer Instructions:

 

Bank
Name:       _________________________________________________

 

Account
Name: _________________________________________________

 

Account
No.    __________________________________________________

 

ABA
No.:        __________________________________________________

 

Beneficiary’s

Name:              ___________________________________________________

 

Bank
Address: __________________________________________________Certain
identified information has been omitted because the omitted information is (i) not material and (ii) would likely cause competitive
harm to OncoCyte Corporation if publicly disclosed. Omitted portions of this exhibit are marked [**].

 

Execution
Copy

 

Development
Agreement

 

This
Development Agreement (“Agreement”), dated and effective as of September 30, 2019 (the “Effective
Date”), is by and between Razor Genomics Inc., a Delaware corporation (“Razor”), OncoCyte
Corporation, a California corporation (“OncoCyte”), and Encore Clinical, Inc., a Delaware corporation
(“Encore”) (each of Razor, OncoCyte, and Encore, collectively, the “Parties,”
or each, individually, a “Party”).

 

Preamble

 

WHEREAS,
the Parties are parties to that certain Subscription and Stock Purchase Agreement, dated as of September 4, 2019 (the “SSPA”),
pursuant to which (i) at the initial closing thereunder (the “Initial Closing”) (A) Razor agreed to
purchase and redeem from Encore shares of Razor’s common stock constituting 14.29% of Razor’s outstanding equity on
a fully-diluted basis and (B) Razor agreed to sell to OncoCyte a number of newly issued shares of Razor preferred stock, constituting
25% of Razor’s outstanding equity on a fully-diluted basis (after giving effect to the redemption), and (ii) after the Initial
Closing, at such times and subject to such conditions as set forth in the SSPA, including the exercise of OncoCyte’s purchase
option thereunder, Encore agreed to sell and transfer to OncoCyte the remaining shares of Razor equity owned by Encore (the consummation
of such transaction, the “Second Closing”);

 

WHEREAS,
Razor owns and/or has all worldwide licensed rights in certain intellectual property rights pertaining to lung cancer prognostic
assays (“Razor Assay”);

 

WHEREAS,
each of Razor, OncoCyte, and Encore shall jointly conduct and assume the operational, financial and management control of prospective
clinical trials pertaining to the Razor Assay (“Clinical Trials”);

 

WHEREAS,
Razor and OncoCyte have the right, duty, and obligation to commercialize and sell the Razor Assay; and

 

WHEREAS,
Encore is a former licensee of the intellectual property rights in the Razor Assay.

 

NOW,
THEREFORE, in consideration of the mutual covenants and terms and conditions set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1.
Definitions. For purposes of this Agreement, any capitalized term used but not defined herein will have the meaning ascribed
to such term in the SSPA.

 

2.
Consulting Agreement. At or prior to the Initial Closing, Encore will enter into a consulting agreement with OncoCyte,
in form and substance reasonably acceptable to Encore and OncoCyte (the “Consulting Agreement”), pursuant
to which Encore, through its personnel, will provide consulting services to or on behalf of OncoCyte in support of the completion
of the Clinical Trial and the commercialization of the Razor Assay and with respect to such other matters with respect to Razor’s
business as reasonably requested by OncoCyte (collectively, the “Services”). Under the Consulting Agreement,
Encore will use its reasonable efforts to timely provide Services as reasonably requested by OncoCyte. The Consulting Agreement
will have a four (4) year term. Compensation paid by OncoCyte to Encore under the Consulting Agreement for provision of the Services
will be equal to $500,000 per year in aggregate, paid monthly in arrears, with such compensation being paid in cash for the first
year of the term of the Consulting Agreement and either in cash or, at OncoCyte’s sole election, in a combination of cash
and shares of Buyer Common Stock in the second through fourth years of the term of the Consulting Agreement, with no more than
[**] of the compensation being paid in shares of Buyer Common Stock during the second year and no more than [**] of the compensation
being paid in shares of Buyer Common Stock during the third and fourth years (with any shares of Buyer Common Stock valued at
the Buyer Common Stock Price). The compensation under the Consulting Agreement will constitute all of the amounts payable for
any Services provided by Encore in connection with the Development Agreement or the License Agreement to be entered into by the
Parties in connection with the SSPA (but excluding fees payable under the Laboratory Agreement and any fees payable to Encore
based on the Approved Budgets for the Clinical Trial.

 

    	 	 	 

     

    

 

3.
Steering Committee. Planning and execution of the Clinical Trial will be overseen by a joint steering committee (the “Steering
Committee”) to be formed prior to the Initial Closing and to be made up of two representatives appointed by OncoCyte
and two representatives appointed by Encore prior to the Initial Closing; provided, that after the Initial Closing, either of
OncoCyte or Encore may replace any representative designated by such Party by providing written notice thereof to the other. Subject
to Section 4 below, the Steering Committee shall have full decision-making authority for the duration of the Clinical Trial
for all design, execution, and termination of the Clinical Trial for any reason prior to completion, with any recommendations,
determinations, decisions or actions of the Steering Committee being made based on simple member majority approval. In the event
that a majority cannot be reached on any given element of Clinical Trial design, execution or termination, with the exception
of any budget approvals or expenditures as stipulated in Section 4 below or any publication approvals in Section 8
below, one of the Steering Committee representatives appointed by Encore will make the final decision with regard to said element.
Notwithstanding the foregoing, Razor will end the Clinical Trial if the FDA or another Governmental Authority (including any quasi-governmental
or certifying board or authority, such as the Institutional Review Board) requires or recommends the termination of the Clinical
Trial (a “Trial Regulatory Termination”). For the avoidance of doubt, any Trial Regulatory Termination
shall not constitute a breach by any Party for purposes of this Agreement.

 

4.
Budget. Prior to the Initial Closing, the Steering Committee will agree upon and approve by majority vote of the members
the design and total budget for the expenses and liabilities for the entire Clinical Trial, broken out by month and year (such
agreed upon budget, as it may be amended, the “Approved Total Budget”) and an annual budget for the
Clinical Trial expenses and liabilities for the upcoming year, broken out by month (such agreed upon budget, as it may be amended,
the “Approved Initial Annual Budget”). Each year after the Initial Closing (promptly prior to the applicable
anniversary of the Initial Closing), the Steering Committee will agree upon and approve by majority vote of the members an annual
budget for the Clinical Trial expenses and liabilities for the upcoming year, broken out by month (such agreed upon budget, as
it may be amended, an “Approved Subsequent Annual Budget” and, any Approved Subsequent Annual Budget
or Approved Initial Annual Budget, as applicable, an “Approved Annual Budget”, and the Approved Annual
Budgets and the Approved Total Budget, collectively, the “Approved Budgets”). In the event that the
Steering Committee cannot achieve majority member approval of an Approved Subsequent Annual Budget, the Approved Total Budget
will continue for such year until the new Approved Subsequent Annual Budget is approved by a majority of the Steering Committee.
At the end of each quarter, the Steering Committee will meet to review and discuss Razor’s expenditures and liabilities
incurred for the Clinical Trial under the Approved Annual Budget then in effect and the Approved Total Budget, and consider in
good faith any potential amendments for the remaining quarters of the Approved Annual Budget and the remaining periods of the
Approved Total Budget (provided, that no changes to an Approved Budget will be made without majority approval of the members of
the Steering Committee). Without the prior approval (by a majority of the members) of the Steering Committee, Razor will not incur
or pay any expenses or liabilities in connection with the Clinical Trial (a) in excess of [**] of the aggregate amount under any
Approved Budget then in effect or (b) [**] of the amount for any aggregate line item (based on nature of cost) under any Approved
Budget then in effect.

 

    	 	 	2

    	 	 	 

    

 

5.
Clinical Trial Reserve; Funding of Clinical Trial by OncoCyte.

 

5.1
Four Million U.S. Dollars ($4,000,000) of the proceeds paid to Razor in the Subscription (the “Clinical Trial Expense
Reserve”) will be set aside and used solely towards the completion of the Clinical Trial, with the Clinical Trial
Expense Reserve being used solely for Clinical Trial expenses that are incurred after the Initial Closing in accordance with the
Approved Budgets (and for the avoidance of doubt, excluding any amounts previously advanced by OncoCyte to Razor as documented
pursuant to the Secured Note). With the exceptions of (i) up to [**] of costs related to renewing or maintaining the Clinical
Trial’s electronic data capture system and/or biostatistics support and (ii) the out-of-pocket costs relating to planned
meetings with key investigators at the World Conference on Lung Cancer in Barcelona on September 7-9, 2019 (clauses (i) and (ii)
together, the “Permitted Pre-Closing Clinical Trial Expenses”), any existing Clinical Trial expenses
or other liabilities that are or have been incurred prior to the Effective Date (“Pre-Closing Clinical Trial Expenses”)
will be borne and paid by Razor using funds other than the Clinical Trial Expense Reserve, and OncoCyte will have no liability
for any Pre-Closing Clinical Trial Expenses.

 

5.2
All expenses for the Clinical Trial through completion of the Clinical Trial (other than Pre-Closing Clinical Trial Expenses)
in excess of the Clinical Trial Expense Reserve up to the total Approved Budgets as determined by the Steering Committee will
be paid directly by OncoCyte on behalf of Razor.

 

6.
Other Payments.

 

6.1
Upon the Initial Closing, OncoCyte will pay One Million U.S. Dollars ($1,000,000) in cash to Encore for having achieved a positive
draft local coverage decision from the Centers for Medicare and Medicaid Services Molecular Diagnostic Services Program (“CMS/MolDX”),
by wire transfer in immediately available funds to such account or accounts as designated by Encore or by delivery of a certified
or bank cashier’s check payable to, or upon the order of, Encore.

 

6.2
In the event of a final positive local coverage decision from CMS/MolDx within twelve (12) months after the Initial Closing, OncoCyte
will promptly thereafter pay Four Million U.S. Dollars ($4,000,000) in cash to Encore, by wire transfer in immediately available
funds to such account or accounts as designated by Encore or by delivery of a certified or bank cashier’s check payable
to, or upon the order of, Encore.

 

6.3
If within [**] after the Initial Closing, Encore is substantially responsible for obtaining funding to OncoCyte or Razor from
a pharmaceutical company for the Clinical Trial, OncoCyte or Razor, as applicable, will pay Encore [**] of the amount actually
received from such a pharmaceutical company within [**] after receipt, by wire transfer in immediately available funds to such
account or accounts as designated by Encore or by delivery of a certified or bank cashier’s check payable to, or upon the
order of, Encore; provided, that if such pharmaceutical company is the company set forth on Schedule 6.3 hereto
or its subsidiaries (the “Identified Pharma Company”), and within [**] after the Initial Closing the
Identified Pharma Company provides funding for the Clinical Trial to OncoCyte or Razor, OncoCyte or Razor will pay [**] of the
amount received to Encore within [**] after receipt, with the total payments to Encore with respect to any funding from the Identified
Pharma Company not to exceed Three Million U.S. Dollars ($3,000,000), irrespective of the total amount paid by the Identified
Pharma Company.

 

    	 	 	3

    	 	 	 

    

 

6.4
Upon completion of enrollment in the Clinical Trial for the full number of patients thereunder (currently estimated to be [**],
subject to the determination of the Steering Committee prior to the Initial Closing), OncoCyte shall issue to the Company Holders
(as defined in the SPA) shares of Buyer Common Stock equal in value to Three Million U.S. Dollars ($3,000,000), with each share
of OncoCyte Common Stock valued at the Buyer Common Stock Price as of the date of issuance; provided, that (i) if Buyer
would be required by this Section 6.4 (together with any shares of Buyer Common Stock issuable to Company Holders under
the SSPA or under the Minority Holder Purchase Agreements) to issue to the Company Holders more than 19.99% of the issued and
outstanding shares of Buyer Common Stock or the outstanding voting power of OncoCyte, in either case as of the date of the SSPA,
prior to giving effect to such issuance, or if such issuance would otherwise require the approval of OncoCyte’s stockholders
pursuant to the rules and regulations of the NYSE American or other applicable law, regulation or rule, then OncoCyte, at its
sole election, may deliver cash in lieu of shares of Buyer Common Stock to the extent that such cash delivery avoids requiring
OncoCyte shareholder approval; and (ii) no fractional shares of Buyer Common Stock will be issued by OncoCyte and any fractional
numbers will be rounded down to the nearest whole share and any fractional amount will instead be paid by OncoCyte in cash. The
payments to the Company Holders under this Section 6.4 shall be allocated among the Company Holders on a pro rata basis
based on (i) prior to the Second Closing, the shares of Razor owned by each such Company Holder at such time and (ii) at or after
the Second Closing, the Purchased Shares (as defined in the SSPA) sold to OncoCyte under the SSPA and the Minority Holder Purchase
Agreements.

 

7.
CLIA Laboratory Costs for Clinical Trial. As set forth in the License Agreement, OncoCyte will assume all costs under Razor’s
Laboratory Agreement with Encore (as amended, including at the Initial Closing, the “Laboratory Agreement”)
associated with the operation of Razor’s CLIA laboratory incurred for periods from and after the Initial Closing in accordance,
including the provision of the Razor Assay for the Clinical Trial.

 

8.
Clinical Trials IP. To the extent permitted under the terms of the Amended and Restated Exclusive License Agreement for
Gene-Based Assays for Cancer Diagnosis and Prognosis, dated as of February 15, 2018, by and between the Regents of the University
of California, acting through the University of California, San Francisco Office of Technology Management, and Razor (as amended,
the “UCSF License”), all of the intellectual property rights to the Clinical Trial, including any new
inventions, improvements or discoveries (the “New IP”), will be jointly owned by Razor and OncoCyte.
Information and data regarding the Clinical Trial and its results may not be published, distributed or otherwise disclosed without
the prior approval of the Steering Committee (by majority of the members).

 

9.
Provision of Personnel, Materials and Services in Connection with the Clinical Trial.

 

9.1
OncoCyte may provide certain of its personnel to perform work in connection with the Clinical Trial, as well as capital expenditures
and materials, and, with prior written approval by Razor on a case-by-case basis (not to be unreasonably withheld, delayed or
conditioned) or otherwise to the extent set forth in an Approved Budget then in effect, will be permitted to charge Razor for
such services, capital expenditures and materials based on internal fully burdened costs and activity driver allocations at cost
(plus a potential markup if required to do so for tax purposes).

 

9.2
Encore may be contracted by Razor or OncoCyte to provide personnel, materials or services to the Clinical Trial beyond the provision
of the Razor Assay (as set forth in the Laboratory Agreement) and the Services, such additional personnel, materials and services
to be expressly designated in the Approved Budget then in effect as extending beyond costs covered by the Laboratory Agreement
and the Consulting Agreement.

 

    	 	 	4

    	 	 	 

    

 

9.3
Any decisions to hire a third party service provider to provide services in connection with the Clinical Trial will be made by
the Steering Committee.

 

10.
Compliance with Laws; Insurance.

 

10.1
Each Party shall comply and shall ensure that its employees, agents, and independent contractors (including subcontractors) comply
with all applicable Laws in the exercise of its rights and performance of its obligations under this Agreement.

 

10.2
Each Party will maintain reasonable and necessary insurance, including Clinical Trial insurance by Razor, the cost of said Clinical
Trial insurance for periods after the Initial Closing to be included in the Approved Budgets and to be paid for either by the
Clinical Trial Expense Reserve or OncoCyte in accordance with Section 5 above.

 

11.
Termination.

 

11.1
This Agreement can be terminated as follows:

 

(a)
by mutual written consent of OncoCyte, Razor and Encore;

 

(b)
by either OncoCyte or Encore, by providing written notice thereof to the other Parties, if the Clinical Trial is ended by either
the Steering Committee or a Trial Regulatory Termination, in either case, prior to completion;

 

(c)
by OncoCyte by providing written notice thereof to the other Parties, if there has been a material breach or violation by Encore
or, prior to the Second Closing, Razor of their respective representations, warranties, covenants or agreements under this Agreement,
the License Agreement, the Consulting Agreement or the Laboratory Agreement and such breach or violation is not cured within [**]
after written notice of such breach or violation is provided by OncoCyte to Encore;

 

(d)
by Encore by providing written notice thereof to the other Parties, if there has been a material breach or violation by OncoCyte
of its representations, warranties, covenants or agreements under this Agreement, the License Agreement, the Consulting Agreement
or the Laboratory Agreement and such breach or violation is not cured within [**] after written notice of such breach or violation
is provided by Encore to OncoCyte; or

 

(e)
by Encore by providing written notice thereof to the other Parties, if the Second Closing Milestone is achieved under the SSPA,
but OncoCyte fails to complete the Second Closing (as contemplated by the SSPA) as a result of the cancellation of the Second
Closing Purchase Option under Section 4.5(d) of the SSPA.

 

11.2
In the event of the termination of this Agreement, the obligations of the Parties under this Agreement will become null and void,
and there shall be no further liability or obligation on the part of any Party or any of their respective Representatives hereunder.
Notwithstanding anything herein to the contrary, no termination of this Agreement shall affect (i) any obligations of the parties
under Sections 2, 3, 4, 5, 8, 13, 15 and this Section 11, which shall
survive any termination of this Agreement (provided, that Sections 2, 3, 4 and 5 shall not survive
any termination pursuant to Section 11.1(b) above) or (ii) any Liability of a Party for a willful breach or violation of
this Agreement or any Fraud Claim against such Party, in either case, prior to such termination.

 

    	 	 	5

    	 	 	 

    

 

12.
[Reserved]

 

13.
Confidentiality.

 

13.1
Each Party acknowledges that it may receive or gain access to the other Party’s non-public proprietary or confidential information
(including any confidential information of third parties where such other Party has an obligation of confidentiality with respect
thereto, “Confidential Information”) in pursuit of the Clinical Trials. Except as provided in Section
13.2 or otherwise agreed in writing by the Parties, each Party, as the receiving party of the other Parties’ Confidential
Information (the “Recipient”), shall: (a) use at least the same standard of care to protect and safeguard
the confidentiality of the Confidential Information of the disclosing party (the “Discloser”) as the
Recipient uses to protect its own Confidential Information (but no less than reasonable care); and (b) not use or disclose, nor
permit to be used or accessed, the Discloser’s Confidential Information for any purpose other than to exercise the Recipient’s
rights or perform its obligations under this Agreement.

 

13.2
Notwithstanding the foregoing obligations of confidentiality and restrictions on use, the Recipient may disclose the Discloser’s
Confidential Information: (a) to the Recipient’s Representatives who (i) have a need to know such Confidential Information
to assist the Recipient or act on its behalf in exercising the Recipient’s rights or performing its obligations under this
Agreement; and (ii) are bound by written agreements containing confidentiality and non-disclosure obligations generally at least
as restrictive as those set forth in this Section 13; provided that the receiving Party shall ensure compliance with, and
be liable for any breach of this Section by any such employees, agents, or independent contractors; (b) as required by
applicable Law or the rules or regulations of the SEC or any applicable securities exchange, in which case the Recipient shall
use commercially reasonable efforts to allow the Discloser reasonable time to comment on any such disclosure, and arrange for
any required filing with respect to, such disclosure, release or announcement in advance of such issuance; or (c) to actual or
prospective acquirers, licensees (including sublicensees), investors, lenders, and other financial or commercial partners (and
to their respective advisors, agents, and representatives), including any pharmaceutical company as contemplated by Section
6.3, to the extent reasonably necessary for evaluating or carrying out the objectives of this Agreement, in each case under
written obligations of confidentiality and non-disclosure at least as restrictive as those set forth in this Section 13.

 

14.
Mutual Representations and Warranties. Each Party represents and warrants to the other Parties that: (a) it is duly organized,
validly existing, and in good standing under the Laws of its jurisdiction of incorporation or organization, and has the full power
and authority to enter into this Agreement and to perform its obligations hereunder; (b) the execution of this Agreement by such
Party’s representative whose signature is set forth at the end hereof has been duly authorized by all necessary corporate
action of such Party; (c) when executed and delivered by such Party, this Agreement constitutes the legal, valid, and binding
obligation of such Party, enforceable against such Party in accordance with its terms; and (d) the execution, delivery, and performance
of this Agreement by such Party does not violate, conflict with, require consent under, or result in any breach of or default
under (i) any applicable Law or (ii) the provisions of any contract, instrument, or understanding to which it is a party or by
which it is bound, including with respect to the Company, the UCSF License.

 

15.
Miscellaneous

 

15.1
Limitation of Liability. To the fullest extent permitted by applicable law, no Party will be liable to the other Parties
under this Agreement for any consequential, incidental, indirect, exemplary, special, punitive, or enhanced damages, or for any
loss of actual or anticipated profits (regardless of how these are classified as damages), whether arising out of breach of contract,
tort (including negligence or strict liability), statute, or otherwise (including the entry into, performance, or breach of this
Agreement), regardless of whether such damage was foreseeable and whether either party has been advised of the possibility of
such damages. The foregoing limitations do not apply to losses arising out of or relating to the gross negligence or willful misconduct
of a party or any of its sublicensees or subcontractors in performing under this Agreement.

 

    	 	 	6

    	 	 	 

    

 

15.2
Arbitration. Any and all disputes, controversies and claims (other than applications for a temporary restraining order,
preliminary injunction, permanent injunction or other equitable relief or application for enforcement of a resolution under this
Section 15.2) arising out of, related to, or in connection with this Agreement or the transactions contemplated hereby
(a “Dispute”) shall be governed by this Section 15.2. A Party must, in the first instance, provide
written notice of any Disputes to the other Parties subject to such Dispute, which notice must provide a reasonably detailed description
of the matters subject to the Dispute. The Parties involved in such Dispute shall seek to resolve the Dispute on an amicable basis
within ten (10) days of the notice of such Dispute being received by such other Parties subject to such Dispute; the “Resolution
Period”); provided, that if any Dispute would reasonably be expected to have become moot or otherwise irrelevant
if not decided within sixty (60) days after the occurrence of such Dispute, then there shall be no Resolution Period with respect
to such Dispute. Any Dispute that is not resolved during the Resolution Period may immediately be referred to and finally resolved
by arbitration pursuant to the then-existing Expedited Procedures (as defined in the AAA Procedures) of the Commercial Arbitration
Rules (the “AAA Procedures”) of the American Arbitration Association (the “AAA”).
Any Party involved in such Dispute may submit the Dispute to the AAA to commence the proceedings after the Resolution Period.
To the extent that the AAA Procedures and this Agreement are in conflict, the terms of this Agreement shall control. The arbitration
shall be conducted by one arbitrator nominated by the AAA promptly (but in any event within five (5) Business Days) after the
submission of the Dispute to the AAA and reasonably acceptable to each Party subject to the Dispute, which arbitrator shall be
a commercial lawyer with substantial experience arbitrating disputes under clinical trial development agreements. The arbitrator
shall accept his or her appointment and begin the arbitration process promptly (but in any event within five (5) Business Days)
after his or her nomination and acceptance by the Parties subject to the Dispute. The proceedings shall be streamlined and efficient.
The arbitrator shall decide the Dispute in accordance with the substantive law of the State of Delaware. Time is of the essence.
Each Party subject to the Dispute shall submit a proposal for resolution of the Dispute to the arbitrator within ten (10) days
after confirmation of the appointment of the arbitrator. The arbitrator shall have the power to order any Party to do, or to refrain
from doing, anything consistent with this Agreement, the SSPA, the other Ancillary Documents and applicable Law, including to
perform its contractual obligation(s); provided, that the arbitrator shall be limited to ordering pursuant to the foregoing power
(and, for the avoidance of doubt, shall order) the relevant Party (or Parties, as applicable) to comply with only one or the other
of the proposals. The arbitrator’s award shall be in writing and shall include a reasonable explanation of the arbitrator’s
reason(s) for selecting one or the other proposal. The seat of arbitration shall be in the State of California, and the language
of the arbitration shall be English.

 

15.3
Governing Law; Jurisdiction; Waiver
of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware
(without giving effect to its choice of law principles). Subject to Section 15.2, for purposes of any Action arising out
of or in connection with this Agreement or any transaction contemplated hereby or thereby, each of the Parties (a) irrevocably
submits to the exclusive jurisdiction and venue of any state or federal court located in the State of California (and any appellate
courts thereof), (b) agrees that service of any process, summons, notice or document by U.S. registered mail to such Party’s
respective address set forth in Section 15.6 shall be effective service of process for any Action with respect to any matters
to which it has submitted to jurisdiction in this Section 15.3, and (c) waives and covenants not to assert or plead, by
way of motion, as a defense or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction
of such court, that the Action is brought in an inconvenient forum, that the venue of the Action is improper or that this Agreement
or the subject matter hereof may not be enforced in or by such court, and hereby agrees not to challenge such jurisdiction or
venue by reason of any offsets or counterclaims in any such Action. The Parties hereby
knowingly, voluntarily and intentionally waive the right any may have to a trial by jury in respect to any litigation based hereon,
or arising out of, under, or in connection with this Agreement and any agreement contemplated to be executed in connection herewith,
or any course of conduct, course of dealing, statements (whether verbal or written) or actions of any Party in connection with
such agreements.

 

    	 	 	7

    	 	 	 

    

 

15.4
Remedies. Except as specifically set forth in this Agreement, any Party having any rights under any provision of this Agreement
will have all rights and remedies set forth in this Agreement and all rights and remedies which such Party may have been granted
at any time under any other contract or agreement and all of the rights which such Party may have under any applicable Law. Except
as specifically set forth in this Agreement, any such Party will be entitled to (a) seek to enforce such rights specifically,
without posting a bond or other security or proving damages or that monetary damages would be inadequate, (b) to recover damages
by reason of a breach of any provision of this Agreement and (c) to exercise all other rights granted by applicable Law. The exercise
of any remedy by a Party will not preclude the exercise of any other remedy by such Party.

 

15.5
Further Assurances. Each Party shall, upon the reasonable request of another Party, promptly execute such documents and
perform such acts as may be necessary to give full effect to the terms of this Agreement.

 

15.6
Notices. Any notice, request, instruction or other document to be given hereunder by a party hereto shall be in writing
and shall be deemed to have been given, (i) when received if given in person or by courier or a courier service, (ii) on the date
of transmission if sent by facsimile or email (with affirmative confirmation of receipt, and provided, that the party providing
notice shall within two (2) Business Days provide notice by another method under this Section 15.6) or (iii) three (3)
Business Days after being deposited in the U.S. mail, certified or registered mail, postage prepaid:

 

	If
        to Encore or, at or prior to the Second Closing, Razor, to:

                                                                      

                                                                     

        Razor
        Genomics Inc.

        150
        N. Hill Drive, Suite 14

        Brisbane,
        CA 94005

        Attn:
        Michael Mann, CEO

        Telephone
        No: [**]

        Email:
        [**]

        
	with
        a copy (which will not constitute notice) to:

                                                                      

        Latham
        & Watkins LLP

        

        140
        Scott Drive

        Menlo
        Park, CA 94025

        Attn:
        Benjamin A. Potter, Esq.

        Facsimile
        No.: [**]

        Telephone
        No: [**]

        Email:
        [**]

        

	 	 
	If
        to Oncocyte or, after the Second Closing, Razor, to:

                                                                                            

        OncoCyte
        Corporation

        1010
        Atlantic Avenue, Suite 102

        Alameda,
        California 94501

        Attn:
        Albert P. Parker, COO

        Telephone
        No: [**]

        Email:
        [**]
	with
        a copy (which will not constitute notice) to:

                                                          

        Ellenoff
        Grossman & Schole LLP

        1345
        Avenue of the Americas, 11th Floor

        New
        York, New York 10105

        Attn:
        Matthew A. Gray, Esq.;

        Robert
        Charron, Esq.

        Facsimile
        No.: [**]

        Telephone
        No.: [**]

        Email:
        [**]

 

or
to such other individual or address as a party hereto may designate for itself by notice given as herein provided.

 

    	 	 	8

    	 	 	 

    

 

15.7
Interpretation. The headings in this Agreement are for reference only and do not affect the interpretation of this Agreement.
For purposes of this Agreement, (a) the words “include,” “includes,” and “including” will
be deemed to be followed by the words “without limitation”; (b) the word “or” is not exclusive; and (c)
the words “herein,” “hereof,” “hereby,” “hereto,” and “hereunder”
refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Sections and Schedules refer
to the Sections of and Schedules attached to this Agreement; (y) to an agreement, instrument, or other document means such agreement,
instrument, or other document as amended, supplemented, and modified from time to time to the extent permitted by the provisions
thereof; and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and
any regulations promulgated thereunder. This Agreement is to be construed without regard to any presumption or rule requiring
construction or interpretation against the party drafting an instrument or causing any instrument to be drafted.

 

15.8
Entire Agreement. This Agreement, together with any other documents referenced or incorporated herein by reference (including
the SSPA, the License Agreement and the Consulting Agreement) and all related schedules, constitutes the sole and entire agreement
of the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings,
agreements, representations, and warranties, both written and oral, with respect to such subject matter.

 

15.9
Assignment; Third Party Beneficiaries. This Agreement may not be assigned by any Party without the prior written consent
of the other Parties hereto, and any attempted assignment in violation of this Section 15.9 will be null and void ab initio;
provided, however, that upon or after the Second Closing, each of OncoCyte and Razor may assign its rights and obligations
hereunder: (i) to any Affiliate of such Party, as applicable (provided, that such assigning Party shall remain primarily responsible
for its obligations hereunder); (ii) to any Person acquiring all or substantially all of the assets of OncoCyte and its Subsidiaries
taken as a whole or all or substantially all of the assets of Razor and its Subsidiaries taken as a whole or a majority of the
outstanding equity securities of OncoCyte or Razor (whether by stock purchase, merger, consolidation or otherwise); provided,
that the assignee expressly assumes the obligations of OncoCyte or Razor, as applicable, hereunder; or (iii) as security to any
Person providing debt financing to OncoCyte or its Affiliates for any of the transactions contemplated by the SSPA or this Agreement.
Subject to the preceding sentence, this Agreement will apply to, be binding in all respects upon and inure to the benefit of the
successors and permitted assigns of each Party. This Agreement is for the sole benefit of the Parties and their successors and
permitted assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the Parties
and such successors and permitted assigns, any legal or equitable rights hereunder. Without limiting the foregoing, the Minority
Holders shall not have any right hereunder to make any claims against OncoCyte with respect to Section 6.4.

 

15.10
Amendment; Modification; Waiver. This Agreement may only be amended, modified, or supplemented by an agreement in writing
signed by each of the Parties. No waiver by any Party of any of the provisions hereof will be effective unless expressly set forth
in writing and signed by the waiving Party. Except as otherwise set forth in this Agreement, no failure to exercise, or delay
in exercising, any rights, remedy, power, or privilege arising from this Agreement will operate or be construed as a waiver thereof;
nor will any single or partial exercise of any right, remedy, power, or privilege hereunder preclude any other or further exercise
thereof or the exercise of any other right, remedy, power, or privilege.

 

15.11
Severability. If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such
invalidity, illegality, or unenforceability will not affect any other term or provision of this Agreement or invalidate or render
unenforceable such term or provision in any other jurisdiction. Upon a determination that any term or other provision is invalid,
illegal, or unenforceable, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent
of the Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated
as originally contemplated to the greatest extent possible.

 

15.12
Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which
together will be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email, or other
means of electronic transmission will be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

{Remainder
of Page Left Blank; Signature Page Follows}

 

    	 	 	9

    	 	 	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement effective as of the Effective Date.

 

	 	OncoCyte:
	 	 
	 	ONCOCYTE
    CORPORATION
	 	 	 
	 	By:
    	/s/
    Ron A. Andrews
	 	Name:
    	Ron
    A. Andrews
	 	Title:	President
    and Chief Executive Officer
	 	 	 
	 	Encore:
	 	 
	 	ENCORE
    CLINICAL, INC. 
	 	 	 
	 	By:
    	/s/
    Michael Mann
	 	Name:
    	Michael
    Mann
	 	Title:
    	Chief
    Executive Officer
	 	 	 
	 	Razor:
	 	 
	 	RAZOR
    GENOMICS INC.
	 	 	 
	 	By:
    	/s/
    Michael Mann
	 	Name:
    	Michael
    Mann
	 	Title:
    	Chief
    Executive Officer

 

    	 	 	10

    	 	 	 

    

 

Schedule
6.3

Identified
Pharma Company

 

[**]

 

    	 	 	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]